Scilex Holding Co (SCLX)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$5.42+2.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · SCLX
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-25.0) + peer(0.2*8.3) + term(0.0) → -7.09% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. Scilex Holding Company (the “Company”) is providing certain preliminary unaudited financial results for the quarter ended September 30, 2024 based on currently available information. The Company’s independent auditor has not reviewed or audited these preliminary estimated financial results. The Company’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financi…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. Scilex Holding Company (the “Company”) is providing certain preliminary unaudited financial results for the month ended July 31, 2024 based on currently available information. The Company’s independent auditor has not reviewed or audited these preliminary estimated financial results. The Company’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data…
Results of Operations and Financial Condition. Scilex Holding Company (the “Company”) is providing certain preliminary unaudited financial results for the month ended June 30, 2024 and quarter ended June 30, 2024 based on currently available information. The Company’s independent auditor has not reviewed or audited these preliminary estimated financial results. The Company’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges.…
Results of Operations and Financial Condition. Scilex Holding Company (the “Company”) is providing certain preliminary unaudited financial results for the quarter ended March 31, 2024 based on currently available information. The Company’s independent auditor has not reviewed or audited these preliminary estimated financial results. The Company’s actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial d…
Financial Statements and Exhibits. On February 29, 2024, the Company filed with the SEC a preliminary prospectus supplement (the “Preliminary Prospectus Supplement”) and on March 4, 2024, the Company filed with the SEC the Final Prospectus Supplement (together with the Preliminary Prospectus Supplement, the “Prospectus Supplement”) pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”), relating to the Offering. The Company disclosed in the Prospectus S…